Bruker vs Charles River Laboratories
Charles River Laboratories is the larger business, with $4.02bn of revenue in fiscal 2025 against $3.44bn for Bruker (1.2 times as much). Bruker grew faster (2.1% against -0.9%). Bruker kept more of each dollar of sales as profit: a net margin of -0.3% against -3.6%. Charles River Laboratories carries less debt relative to equity (67.6% against 76.1%).
| Latest fiscal year | BrukerBRKR, 2025 | Charles River LaboratoriesCRL, 2025 |
|---|---|---|
| Revenue | $3.44bn | $4.02bn |
| Revenue growth | 2.1% | -0.9% |
| Net income | −$8.6m | −$144m |
| Operating margin | 2.0% | 0.6% |
| Net margin | -0.3% | -3.6% |
| Return on equity | -0.4% | -4.4% |
| Free cash flow | $43.3m | $518m |
| Cash | $299m | $214m |
| Total debt | $1.87bn | $2.14bn |
| Debt to equity | 76.1% | 67.6% |
| Dividend per share | — | — |
| Dividend yield | 0.3% | — |
| Share buybacks | $10.0m | $361m |
| Employees | 11,085 | 19,700 |
| Market value | $8.56bn | $16.81bn |
| Price vs our value range | Above our value range | Above our value range |
| Moat score | 66 (Moderate) | 60 (Moderate) |
| Insider trades, 12 months | 0 buys, 16 sales | 2 buys, 21 sales |